Western blotting analysis further confirmed the substantial upregulation of p21 protein expression and the downregulation of pAKTS473 levels with this combination, suggesting that the combination of hERG activators with AKT inhibitors holds promise as a promising therapeutic strategy in the treatment of breast cancer. The gene discussed is KCNH2; the disease is breast carcinoma.